EPO and anemia (phenotype): Clinically, in addition to recombinant human erythropoietin analogs, prolyl hydroxylase (PH) inhibitors to stabilize the expression of hypoxia‐inducible factor (HIF) protein were recently approved for the treatment of anemia in chronic kidney disease.